Hypothesis

Senolytic clearance of p16^high^ senescent cells lowers the inflammatory secretome that impedes chromatin accessibility, allowing subsequent OSK‑mediated partial reprogramming to reset epigenetic age more durably.

Rationale

• Dasatinib + quercetin (D+Q) intermittently removes senescent cells and reduces SASP factors 1, 2.
• Persistent SASP maintains NF-kB signaling, which sustains heterochromatin formation at loci required for pluripotency factor binding 3.
• Chemical reprogramming cocktails (C1-C6) open chromatin and restore youthful transcription within days, but their efficiency drops in inflamed microenvironments 4.
• Removing SASP therefore creates a permissive environment for OSK or chemical factors to engage target genes without triggering DNA damage responses.

Novel Mechanistic Insight

We propose that senolytic‑induced reduction of IL-1a and IL-6 leads to decreased STAT3 phosphorylation in neighboring stromal cells, which in turn diminishes HDAC1 recruitment to promoters of senescence‑associated genes. Lower HDAC1 activity increases histone H3K27ac levels, facilitating OSK binding and downstream activation of renewal pathways. This epigenetic priming is independent of direct drug effects on the reprogramming factors.

Experimental Design

Model: Humanized mice bearing liver‑derived senescent hepatocytes transplanted alongside immunocompetent stroma. Groups (n=10 per group):

1. Vehicle control.
2. D+Q alone (2‑day cycle, repeat monthly for 3 months).
3. OSK mRNA lipid nanoparticles alone (weekly for 4 weeks).
4. Sequential D+Q followed 48 h later by OSK mRNA (same schedule as group 3).
5. Chemical cocktail C1‑C6 alone (topical/application weekly).
6. Sequential D+Q then C1‑C6. Endpoints (measured at 0, 6, 12 weeks):

• Senescent cell burden via p16^INK4a^ immunostaining and circulating SASP (IL-1a, IL-6) ELISA.
• Chromatin accessibility ATAC-seq on isolated hepatocytes.
• Biological age metrics: liver DNA methylation clock, albumin secretion, fibrosis score (Sirius Red).
• Safety: CBC for thrombocytopenia, liver enzymes. Falsifiable Prediction: If senolytic priming does not enhance reprogramming, groups 4 and 6 will show no significant improvement in epigenetic age or functional readouts over groups 3 and 5 alone. Conversely, a statistically significant reduction in methylation age (>1.5 years) and SASP levels only in the sequential groups would support the hypothesis.

Potential Confounds and Controls

• Include a D+Q‑only group with delayed OSK to rule out carry‑over drug toxicity.
• Use a senolytic‑resistant senescent line (overexpressing BCL‑XL) to confirm that effects depend on actual clearance.
• Monitor for transient dedifferentiation markers (AFP, CK19) to ensure reprogramming stays partial.

Translational Outlook

Positive results would justify a first‑in‑human trial where patients receive a short senolytic lead‑in before ER‑100 (OSK‑based) administration for liver fibrosis, addressing the durability gap noted in current epigenetic reprogramming studies 5, 6.